Fibrin Or Derivative Affecting Or Utilizing Patents (Class 514/13.6)
-
Publication number: 20120114682Abstract: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.Type: ApplicationFiled: July 9, 2010Publication date: May 10, 2012Inventor: Thomas Harrison Barker
-
Patent number: 8133580Abstract: The invention relates to an article comprising a coating, which coating comprises at least two layers, of which the inner layer is a primer layer, comprising a supporting polymer network which is composed of a supporting polymer selected from the group consisting of polyethers and polythioethers, including copolymers thereof, the supporting network optionally comprising a functional non-ionic hydrophilic polymer entangled in the supporting polymer network; and the outer layer is a functional layer comprising a functional non-ionic hydrophilic polymer and a polyelectrolyte.Type: GrantFiled: December 11, 2006Date of Patent: March 13, 2012Assignee: DSM IP Assets B.V.Inventors: Aylvin Jorge Angelo Athanasius Dias, Guido Joseph Elisabeth Hensen, Johannes Wilhelmus Belt, Marnix Rooijmans, Nicolaes Hubertus Maria De Bont, Edwin Peter Kennedy Currie
-
Patent number: 8119597Abstract: The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived, for example, from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.Type: GrantFiled: August 22, 2008Date of Patent: February 21, 2012Assignee: Paion GmbHInventors: Mariola Sohngen, Wolfgang Sohngen, Wolf-Dieter Schleuning, Robert Medcalf
-
Publication number: 20110318375Abstract: A group of peptides has been isolated from the serum of domesticated mammals and then identified through the use of mass spectrometry. These peptides are byproducts of fibrinogen activation and the complement cascade. The peptides of greatest activity are the activated forms of fibrinopeptide A and fibrinopeptide B {activated by the removal of the terminal Arginine), and an immunomodulatory fragment of Complement Component 3.Type: ApplicationFiled: March 9, 2010Publication date: December 29, 2011Inventors: Mitchell J. Melling, Wade M. Melling
-
Publication number: 20110319331Abstract: The invention relates to the use of fibrinogen for manufacturing a medicinal product for use in the prevention or treatment of severe acute haemorrhage, the medicinal product being intended for administration in an amount equal to at least 4.5 g of fibrinogen in a single dose.Type: ApplicationFiled: March 5, 2010Publication date: December 29, 2011Applicant: Laboratoire Francais Du Fractionnement Et Des BiotInventors: Caroline Teboul, Bruno Padrazzi
-
Publication number: 20110318401Abstract: The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.Type: ApplicationFiled: April 18, 2011Publication date: December 29, 2011Inventors: Robert J. Hariri, Janice M. Smiell
-
Publication number: 20110293722Abstract: A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 ?m, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent.Type: ApplicationFiled: December 6, 2009Publication date: December 1, 2011Applicant: TECHION RESEARCH AND DEVELOPMENT FOUNDATION LTD.Inventors: Tamar Kaully, Shulamit Levenberg
-
Patent number: 8067373Abstract: The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R1 and R2 are either the same or different, wherein R1 and R2 are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z1 is selected from the group consisting of histidine and proline, wherein Z2 is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation.Type: GrantFiled: October 9, 2008Date of Patent: November 29, 2011Assignee: Fibrex Medical Research & Development GmbHInventor: Peter Petzelbauer
-
Publication number: 20110287068Abstract: There is provided compositions-of-matter comprising fibrin or fibrinogen crosslinked with at least one reducing sugar.Type: ApplicationFiled: December 31, 2009Publication date: November 24, 2011Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Sandu Pitaru, Naphtali Savion
-
Publication number: 20110280857Abstract: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.Type: ApplicationFiled: November 15, 2010Publication date: November 17, 2011Inventors: Matthew Dowling, Srinivasa Raghavan
-
Publication number: 20110251566Abstract: According to an illustrative embodiment a method to promote healing of a wound is provided comprising contacting the wound with a biologically active composition comprising a lipoic acid derivative and gelatin. In another embodiment a wound dressing is provided comprising a scaffold coated with a biologically active composition comprising a lipoic acid derivative. In a further embodiment, a system is provided for treating a tissue site of a patient, the system comprising a reduced-pressure source to supply reduced pressure, a manifold to distribute reduced pressure to a tissue site and a scaffold coated with a biologically active composition comprising a lipoic acid derivative. Methods for producing such a system and scaffold are also disclosed.Type: ApplicationFiled: April 9, 2010Publication date: October 13, 2011Inventors: DMITRY ZIMNITSKY, Jenny Finkbiner
-
Publication number: 20110223128Abstract: The present invention provides compositions and methods to regulate embolic occlusion of the microvasculature. In particular, the present invention inhibits extravasation of emboli from microvasculature resulting in increased occlusion (e.g., by administering a MMP 2/9 inhibitor locally to a subject).Type: ApplicationFiled: March 10, 2011Publication date: September 15, 2011Applicant: Northwestern UniversityInventors: Jaime Grutzendler, Carson K. Lam, Taehwan Yoo
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Publication number: 20110190812Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.Type: ApplicationFiled: February 4, 2011Publication date: August 4, 2011Applicant: Baxter AktiengesellschaftInventors: Heinz REDL, Guenther Schlag, Irmgard Schlag, Johann Eibl
-
HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE
Publication number: 20110171310Abstract: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.Type: ApplicationFiled: November 30, 2010Publication date: July 14, 2011Applicant: ALLERGAN INDUSTRIE, SASInventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost -
Patent number: 7968682Abstract: Provided are degradation-resistant fibrinogen sealants comprising a first composition comprising one or more of fibrinogen ?A/?? heterodimers and/or fibrinogen ??/?? homodimers and a second composition comprising thrombin and, optionally, degradation-resistant fibrinogen sealants disclosed herein may further comprise Factor XIII and calcium. Degradation-resistant fibrinogen sealants are suitable for the treatment of trauma, particularly vascular trauma.Type: GrantFiled: December 12, 2007Date of Patent: June 28, 2011Assignee: Oregon Health & Science UniversityInventor: David H. Farrell
-
Publication number: 20110150973Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.Type: ApplicationFiled: April 10, 2009Publication date: June 23, 2011Inventors: Gary L. Bowlin, David G. Simpson, James R. Bowman, Stephen W. Rothwell
-
Publication number: 20110152193Abstract: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.Type: ApplicationFiled: February 25, 2011Publication date: June 23, 2011Applicant: DYAX CORP.Inventors: William Markland, Robert C. Ladner
-
Publication number: 20110142907Abstract: Provided herein are polymeric adhesives which may be cured by inductive heating and which are suitable for treating tissue in an individual to effect a weld between one or more tissues or between a tissue and at least one non-tissue substrate. Also provided are methods using the adhesives and methods of manufacture.Type: ApplicationFiled: November 30, 2010Publication date: June 16, 2011Inventors: Kevin S. Marchitto, Stephen T. Flock, Amy Benedict
-
Publication number: 20110071498Abstract: Methods and apparatus for a free-standing biodegradable patch suitable for medical applications, especially intravascular, minimally-invasive and intraoperative surgical applications are provided, wherein the patch comprises a free-standing film or device having a mixture of a solid fibrinogen component and a solid thrombin component that, when exposed to an aqueous environment, undergoes polymerization to form fibrin. In alternative embodiments the patch may comprise a solid fibrinogen component, with or without an inorganic calcium salt component. The patch may take a non-adherent form during delivery to a target location within a vessel or tissue, and thereafter may be activated to adhere to vessel wall or tissue, and may include a number of additives, including materials to improve the mechanical properties of the patch, or one or more therapeutic or contrast agents.Type: ApplicationFiled: September 17, 2010Publication date: March 24, 2011Inventors: Dorna Hakimimehr, Raoul Bonan
-
Publication number: 20110071083Abstract: A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular weight (HMW) fibrinogen leads to a fibrin having accelerated angiogenesis properties, while the use of low-molecular weight (LMW and/or LMW?) fibrinogen leads to fibrin having decelerated angiogenesis properties. The use of HMW fibrinogen when setting up angiogenesis tests results in that the tests require less time. Fibrin sealants on the basis of HMW fibrinogen can be used for burns, to promote wound healing or to inhibit scar tissue. Fibrin sealants on the basis of LMW or LMW? fibrinogen are useful to inhibit adhesions and tumor growth, for instance after surgical operations.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Applicant: Nederlandse Organisatie Voor Toegepast-Natuurwentenschappelijk Onderzoek TNPInventors: Monica Petronella Maria de Maat, Pieter Koolwijk
-
Patent number: 7897574Abstract: The invention is concerned with the use of a peptide comprising the N-terminal sequence Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (SEQ ID NO: 1) or any allelic variant or derivative of said peptide possessing the biological property of matching the inducible VE-cadherin binding motif on the B?-chain (i.e. B?15-42) of human fibrin for the preparation of a pharmaceutical preparation for the treatment of shock, more specifically of hemorrhagic shock.Type: GrantFiled: November 10, 2006Date of Patent: March 1, 2011Assignee: Ikaria Development Subsidiary Two LLCInventors: Peter Petzelbauer, Rainer Henning
-
Publication number: 20110045051Abstract: The present invention describes an extracellular matrix comprising human platelet derived growth factors, that permits the maximising of therapeutic efficacy, combining the benefits of both components, to result in a more efficient and rapid integration of the matrix up to the structurally organised reconstruction of the neoformed tissue “in vivo”Type: ApplicationFiled: April 3, 2009Publication date: February 24, 2011Inventor: Carlo Mirabella
-
Patent number: 7893030Abstract: The present invention relates to a chromogenic test reagent which comprises a chromogenic peptide substrate and an inhibitor of fibrin polymerization, which is particularly suitable for being used in coagulation-diagnostic tests and which is distinguished by the fact that it exhibits a nigh degree of stability and/or a long shelf life in the liquid state.Type: GrantFiled: January 20, 2006Date of Patent: February 22, 2011Assignee: Siemens Healthcare Diagnostics Products GmbHInventor: Thilo Henckel
-
Publication number: 20110034388Abstract: Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., RGD-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells. Also provided are methods of making compositions that include fibrin microthreads. Also provided are methods for using the compositions to repair or ameliorate damaged or defective organs or tissues.Type: ApplicationFiled: March 15, 2007Publication date: February 10, 2011Inventors: Kevin G. Cornwell, George D. Pins, Kristen Billiar
-
Publication number: 20110028396Abstract: It is an object of the present invention to attach a biopolymer composition to a synthetic polymer substrate without the use of a toxic adhesive. The present invention provides a medical composition, wherein a synthetic polymer substrate and a composition mainly composed of a biopolymer directly adhere to each other due to dissolution of the surfaces thereof.Type: ApplicationFiled: March 30, 2009Publication date: February 3, 2011Applicant: FUJIFILM CORPORATIONInventors: Shouji Ooya, Kentaro Nakamura
-
Publication number: 20110027378Abstract: The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which is substantially homogenously dispersed throughout the continuous liquid phase, methods for making such compositions, medical devices that contain sterilized hemostatic compositions disposed therein and methods of making such devices.Type: ApplicationFiled: October 11, 2010Publication date: February 3, 2011Applicant: ETHICON, INC.Inventors: Sanyog M. PENDHARKAR, Anne J. GORMAN, Guanghui ZHANG, Ada RIVERA, Dwayne Lee LOONEY, Thomas Lee CRAVEN
-
Publication number: 20110009324Abstract: The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are either free or bound to the substrates thereof and act against the therapeutic protein(s) present.Type: ApplicationFiled: September 10, 2010Publication date: January 13, 2011Inventor: Johann Eibl
-
Publication number: 20100331254Abstract: Provided is a pulverized fibrin clot and a pharmaceutical composition including a pulverized fibrin clot. The pharmaceutical composition may contain the pulverized fibrin clot suspended in a gel such as cross-linked hyaluronic acid. The pharmaceutical composition may be in a form suitable for injection and may be used, for example, in the treatment of connective tissue, such as skin connective tissue. Also provided is a method for preparing a pulverized fibrin clot as well as a method for treating connective tissue using the pharmaceutical composition.Type: ApplicationFiled: December 25, 2008Publication date: December 30, 2010Applicant: METAMOREFIXInventors: Ascher Shmulewitz, Mazal Dahan, Raphael Gorodetsky
-
Publication number: 20100318120Abstract: A hemostatic material, production method, delivery method, and apparatus are disclosed. The hemostatic material includes a peptide that preferentially selects exposed endothelial cells for bonding. The peptide is conjugated with a hemostatic agent (e.g., chitosan) to produce a peptide conjugated hemostatic agent. The peptide conjugated hemostatic agent is suspended in a flowable delivery medium that delivers the material to the endothelial cells to stop or reduce bleeding. An apparatus for delivering the hemostatic material includes a conformable covering for sealing off and maintaining an internal pressure in an injury cavity, a delivery port for delivering hemostatic material into the cavity, and a check valve that opens when a predetermined pressure is reached. Methods for producing the hemostatic material and using the apparatus are also disclosed herein.Type: ApplicationFiled: June 15, 2010Publication date: December 16, 2010Inventor: John Howard Gordon
-
Publication number: 20100316648Abstract: The invention relates to C9orf46 homolog, a novel murine membrane protein, and its orthologs in human, mouse and all other species, termed Plg-RKT, or analogs, thereof and the isolation method. The function of this molecule is to bind to plasminogen, plasminogen fragments such as angiostatin1 and other plasminongen fragments having angiostatic activity, tissue plasminogen activator and Lipoprotein(a). Plasminogen receptors function to modulate cell surface proteolysis and physiological and pathophysiological processes requiring cell migration, including, but not limited to, cell migration during inflammation, tissue remodeling, wound healing, tumor cell invasion and metastasis, skeletal myogenesis, neurite outgrowth. Plasminogen receptors also modulate apoptosis and cell death.Type: ApplicationFiled: February 6, 2009Publication date: December 16, 2010Inventors: Lindsey A. Miles, John Yates, Emily I. Chen, Nagyung Baik, Robert J. Parmer
-
Patent number: 7851447Abstract: The subject invention pertains to compositions and methods for promoting repair of damaged nerve tissue. The compositions and methods of the subject invention can be employed to restore the continuity of nerve interrupted by disease, traumatic events or surgical procedures. Compositions of the subject invention comprise one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue. The invention also concerns methods for promoting repair of damaged nerve tissue using the present compositions and nerve tissue treated according to such methods. The invention also pertains to kits for nerve repair.Type: GrantFiled: August 13, 2002Date of Patent: December 14, 2010Assignee: University of Florida Research Foundation, Inc.Inventor: David F. Muir
-
Publication number: 20100310658Abstract: The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs.Type: ApplicationFiled: June 8, 2010Publication date: December 9, 2010Inventors: Gary L. Bowlin, Gary E. Wnek, David G. Simpson, Philippe Lam, Marcus E. Carr, JR.
-
Publication number: 20100279925Abstract: The present invention provides methods for the local treatment of acute and chronic extravascular pulmonary fibrin deposition and/or reducing unwanted effects associated with systemic administration of natural anticoagulants to a subject via airway administration to the subject by intratracheal, intrabronchial or intraalveolar routes of site-inactivated FVIIa or biologically active derivatives thereof.Type: ApplicationFiled: June 23, 2006Publication date: November 4, 2010Inventor: Lars Otto Uttenthal
-
Publication number: 20100254900Abstract: Compositions and methods for manufacturing polymers are disclosed. Compositions include novel plastics, including films and shaped forms comprising polymer matrices that are biologically compatible and biodegradable. Such plastics may comprise polymers derived from natural sources. Further, such plastics are useful in biological systems for wound repair, implants, stents, drug encapsulation and delivery, and other applications. The disclosed methods comprise mild manufacturing processes such that various additives, such as biologically active proteins, sugars, lipids, and the like may be incorporated into the polymer matrix without subsequent loss of bioactivity during processing. Additionally, methods of manufacture for controlling mechanical properties, such as elasticity, pliancy, and the porosity of such plastics are disclosed.Type: ApplicationFiled: July 28, 2006Publication date: October 7, 2010Inventors: Phil G. Campbell, Lee E. Weiss, Jason Smith